Innate Pharma (IPH.PA ) Presents New Data for Proprietary Programs Targeting TLR3 and KIR3DL2
4/12/2013 9:22:19 AM
More...
|
Innate Pharma (IPH.PA ) Release: Annual Results for 2012: Significant Advance for Four Drug Candidates and Strong Cash Position
3/5/2013 9:24:25 AM
More...
|
Innate Pharma (IPH.PA ): Phase I Clinical Trial of IPH2102/BMS-986015 in Combination With Ipilimumab Announced
12/19/2012 8:45:39 AM
More...
|
Innate Pharma (IPH.PA ) (Euronext Paris: FR0010331421 - IPH): First Patient Treated in the EffiKIR Trial
12/17/2012 9:29:00 AM
More...
|
Bristol-Myers Squibb Company (BMY), Innate Pharma (IPH.PA ) Announce $465 Million Deal for an Investigational Immuno-Oncology Biologic; Innate to Receive $35 Million Upfront, Shares Soar
7/6/2011 12:53:26 PM
More...
|
Appointment of Catherine Moukheibir to the Executive Board of Innate Pharma
5/5/2011 10:53:43 AM
More...
|
Innate Pharma and TRANSGENE (TRGNY) Announce the Creation of Platine Pharma Services, a New Company Specialized in Immunomonitoring Services
5/4/2011 11:16:24 AM
More...
|
Innate Pharma Updates on its Next Meetings with Analysts and Investors
3/23/2011 2:18:48 PM
More...
|
Innate Pharma Drops IPH 1101 Development
3/4/2011 8:15:03 AM
More...
|
Innate Pharma Reports 2010 Financial Results and Updates on Its Drug Candidates
3/2/2011 11:40:39 AM
More...
|
|